Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC-AF Asundexian vs Apixaban in Atrial Fibrillation
CTR20230520Phase 3Terminated
- Sponsor
- ---
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asundexian in Atrial fibrillation (AFib) (2 arms). Primary endpoints: Time to first occurrence of stroke or systemic embolism (composite), Time to first occurrence of ISTH major bleeding and 1 more. Started Mar 2023; status: terminated.
02
Drugs
asundexian
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on CTR20230520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230520.